Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

201

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

201 results for “Glutamate”

Learn how ShareScore rates datasets ↗
ClinicalTrials.gov32/100

Ketamine Associated ACC GABA and Glutamate Change and Depression Remission:

ClinicalTrials.gov study NCT03573349. IPD Sharing: NO. Countries: 1. Publications: 3.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

A Glutamate Transporter GLT1, in the Treatment of Bipolar Disorder

ClinicalTrials.gov study NCT00512616. IPD Sharing: Not stated. Countries: 1. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Evenamide, a Glutamate Release Modulator, as Add-On to Standard of Care in Subjects With Documented Treatment-Resistant Schizophrenia

ClinicalTrials.gov study NCT07184619. IPD Sharing: UNDECIDED. Countries: 1. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Glutamate Excitotoxicity in Brain Metastases From Lung, Breast and Melanoma Treated With Stereotactic Radiosurgery

ClinicalTrials.gov study NCT04785521. IPD Sharing: NO. Countries: 1. Publications: 7.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Effect of N-acetylcysteine on Brain Glutamate

ClinicalTrials.gov study NCT02483130. IPD Sharing: Not stated. Countries: 1. Publications: 3.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Relationship Between Efficacy of Lumateperone and Brain Glutamate and Dopamine

ClinicalTrials.gov study NCT05890768. IPD Sharing: NO. Countries: 1. Publications: 32.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Increasing Vegetable Intake Using Monosodium Glutamate: A Reduced-Effort Intervention

ClinicalTrials.gov study NCT05591612. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Dual Anti-glutamate Therapy in Super-refractory Status Epilepticus After Cardiac Arrest

ClinicalTrials.gov study NCT05756621. IPD Sharing: UNDECIDED. Countries: 1. Publications: 10.

restrictedIPD-UNDECIDEDFeb 2026View details →
dryad32/100

RNAseq data from: Medial prefrontal cortex samples of glutamate dehydrogenase-deficient mice, stress-exposed or -naive, and their Nestin-Cre+ controls

Open the record for dataset details and reuse information.

publicJun 2023View details →
dryad28/100

Data from: The UBR-1 ubiquitin ligase regulates glutamate metabolism to generate coordinated motor pattern in Caenorhabditis elegans

UBR1 is an E3 ubiquitin ligase best known for its ability to target protein degradation by the N-end rule. The physiological functions of UBR family proteins, however, remain not fully understood. We found that the functional loss of C. elegans UBR-1 leads to synchronized motor neuron activation, preventing body bending when animals generate reversal movements. This motor deficit is rescued by removing GOT-1, a transaminase that converts aspartate to glutamate. Both UBR-1 and GOT-1 are critically required in premotor interneurons of the reverse motor circuit to regulate the motor pattern. ubr-1 and got-1 mutants exhibit elevated and decreased glutamate level, respectively. These results raise an intriguing possibility that UBR proteins regulate glutamate metabolism.

opencc-zeroDec 2017View details →
zenodo28/100

Figure 1 from: Hristov M, Sabit Z, Kirilov T, Bakalov D, Tzoneva R, Apostolova S, Georgieva I, Andreeva-Gateva P (2024) Effects of riboflavin on hyperalgesia and serum glutamine-to-glutamate ratio in rats with painful diabetic neuropathy. Pharmacia 71: 1-7. https://doi.org/10.3897/pharmacia.71.e120921

Figure 1 Effects of riboflavin on changes in pain threshold were investigated using the paw pressure test. Streptozotocin administration significantly induced mechanical hyperalgesia by reducing the mechanical threshold and enhancing paw withdrawal responses, while supplementation with Vitamin B2 effectively mitigated mechanical hyperalgesia. Significant differences compared to the control group (Normal) are denoted as *P < 0.05, while significant differences compared to the diabetic group (Diabetic) are denoted as ##P < 0.01. n=8 animals per group.

opencc-by-4.0Mar 2024View details →
zenodo28/100

Figure 3 from: Hristov M, Sabit Z, Kirilov T, Bakalov D, Tzoneva R, Apostolova S, Georgieva I, Andreeva-Gateva P (2024) Effects of riboflavin on hyperalgesia and serum glutamine-to-glutamate ratio in rats with painful diabetic neuropathy. Pharmacia 71: 1-7. https://doi.org/10.3897/pharmacia.71.e120921

Figure 3 Effects of riboflavin on changes in pain threshold were investigated using the formalin test. The ends of the boxes depict the 25th and 75th percentiles, with a line at the median, while error bars extend to the 10th and 90th percentiles. During phase 1 of the formalin test, neither the vehicle-treated diabetic group nor the introduction of riboflavin showed significant changes in nociceptive behavior compared to the control group. In phase 2, the vehicle-treated diabetic group exhibited increased nociceptive behavior, while the addition of 25 mg or 50 mg of vitamin B2 significantly alleviated formalin-induced hyperalgesia. Significant differences compared to the control group (Normal) are indicated as *P < 0.05. Significant differences compared to the diabetic group (Diabetic) are indicated as #P < 0.05. n=8 animals per group.

opencc-by-4.0Mar 2024View details →
zenodo28/100

Figure 2 from: Hristov M, Sabit Z, Kirilov T, Bakalov D, Tzoneva R, Apostolova S, Georgieva I, Andreeva-Gateva P (2024) Effects of riboflavin on hyperalgesia and serum glutamine-to-glutamate ratio in rats with painful diabetic neuropathy. Pharmacia 71: 1-7. https://doi.org/10.3897/pharmacia.71.e120921

Figure 2 Effects of riboflavin on changes in pain threshold were investigated using the cold plate. Streptozotocin administration induced significant cold-induced hyperalgesia, alleviated notably by riboflavin in drinking water. Significant differences compared to the control group (Normal) are indicated as ***P < 0.001. Significant differences compared to the diabetic group (Diabetic) are indicated as #P < 0.05 and ###P < 0.001. n=8 animals per group.

opencc-by-4.0Mar 2024View details →
zenodo28/100

Figure 4 from: Hristov M, Sabit Z, Kirilov T, Bakalov D, Tzoneva R, Apostolova S, Georgieva I, Andreeva-Gateva P (2024) Effects of riboflavin on hyperalgesia and serum glutamine-to-glutamate ratio in rats with painful diabetic neuropathy. Pharmacia 71: 1-7. https://doi.org/10.3897/pharmacia.71.e120921

Figure 4 Box plot illustrating the effect of riboflavin supplementation on the serum glutamine-to-glutamate ratio in diabetic rats. The ends of the boxes depict the 25th and 75th percentiles, with a line at the median, while error bars extend to the 10th and 90th percentiles. Riboflavin supplementation in the drinking water significantly altered the serum glutamine-to-glutamate ratio in diabetic rats with neuropathic pain, with a significant difference found only between the "Diabetic" and "Diabetic + Rf 50 mg" groups. Significant differences compared to the diabetic group (Diabetic) are indicated as *p < 0.05. n=8 animals per group.

opencc-by-4.0Mar 2024View details →
zenodo28/100

Raw data for: Okada et al., Photopharmacological modulation of hippocampal local field potential by caged-glutamate with MicroLED probe

<p>Matlab data of LFPs (sampling rate, 1k/sec; microV)</p>

opencc-by-4.0Jul 2024View details →
dryad28/100

Data from: Glutamate receptor delta2 serum antibodies in paediatric opsoclonus myoclonus ataxia syndrome

Objective: To identify neuronal surface antibodies in opsoclonus myoclonus ataxia syndrome (OMAS) usingcontemporary antigen discovery methodology. Methods: OMAS patient serum IgG immunohistochemistry using age-equivalent rat cerebellar tissue was followed by immunoprecipitation, gel electrophoresis and mass spectrometry. Data are available via ProteomeXchange (identifier PXD009578). This generated a list of potential neuronal surface cerebellar autoantigens. Live cell-based assays (CBA) were used to confirm membrane-surface antigens and adsorb antigen-specific IgGs. The serological results were compared to the clinical data. Results: Four of the six OMAS sera tested bound rat cerebellar sections. Two of these sera with similar immunoreactivities were used in immunoprecipitation experiments using cerebellum from postnatal rat pups (P18). Mass spectrometry identified 12 cell-surface proteins, of which glutamate receptor delta 2 (GluD2), a predominately cerebellar-expressed protein, was found at a threefold higher concentration than the other 11 proteins. Antibodies to GluD2 were identified in 14/16 (87%) OMAS samples, compared with 5/139 (5%) pediatric and 1/38 (2.6%) adult serum controls (p&lt;0.0001), and in 2/4 sera from patients with neuroblastoma without neurological features. Adsorption of positive OMAS sera against GluD2-transfected cells substantially reduced but did not eliminate, reactivity towards cerebellar sections. Conclusion: Autoantibodies to GluD2 are frequent in patients with OMAS, bind to surface determinants and are potentially pathogenic.

opencc-zeroDec 2017View details →
dryad28/100

Targeting metabotropic glutamate receptor 4 for cancer immunotherapy

<p><span><span><span><span><span><span><span><span><span><span><span>The complex mechanism regulating the immunosuppressive tumor microenvironment (TME) remains poorly understood. Here, we reported a novel role of the metabotropic glutamate receptor-4 (GRM4) in suppressing the anti-tumor immunity. We revealed in three murine syngeneic tumor models (B16, MC38, and 3LL) that either genetic knockout (<i>Grm4</i><sup>−/−</sup>) or pharmacological inhibition led to significant delay in tumor growth and synergized with immune checkpoint inhibitors in male mice. Mechanistically, perturbation of GRM4 resulted in a strong anti-tumor immunity by promoting nature killer (NK), CD4<sup>+</sup> and CD8<sup>+</sup> T cells towards an activated, proliferative, and functional phenotype. Single-cell RNA-sequencing and T Cell Receptor (TCR) profiling further defined the clonal expansion and immune landscape changes in CD8<sup>+</sup> T cells. Mechanistically, <i>Grm4</i><sup>-/- </sup>intrinsically activated IFN-g production in CD8<sup>+</sup> T cells through cAMP/CREB-mediated pathway. Our study appears to be of clinical significance as a signature of NK<sup>high</sup>-GRM4<sup>low</sup> and CD8<sup>high</sup>-GRM4<sup>low</sup> correlated with improved survival in melanoma patients. Therefore, targeting GRM4 could be exploited as a new approach for cancer immunotherapy. </span></span></span></span></span></span></span></span></span></span></span></p>

opencc-zeroAug 2021View details →
ClinicalTrials.gov28/100

Understanding Effects of Cannabis Use and Abstinence on Neural Glutamate Homeostasis

ClinicalTrials.gov study NCT05664763. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov28/100

Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression

ClinicalTrials.gov study NCT06511908. IPD Sharing: YES. Countries: 1. Publications: 0.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov28/100

Pilot Study Effect of Sulfasalazine on Glutamate Levels by(Magnetic Resonance Spectroscopy)MRS in Patients With Glioma

ClinicalTrials.gov study NCT01577966. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record